Carcinoma, Merkel Cell: all 138 studies
Page 1 of 2. Open to participants first (39), then studies with results posted, then the rest; newest registration first within each.
- A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid TumorsRecruitingNCT07749586Phase 1/2
- Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO TrialNot yet recruitingNCT07576725Phase 2
- ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1Not yet recruitingNCT07472322Phase 1/2
- Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor CemiplimabRecruitingNCT07387198Phase 2
- A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)RecruitingNCT07302347Phase 1/2
- TIL Therapy in cSCC and MCCRecruitingNCT07288073Phase 2
- The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding AreasRecruitingNCT07285044Phase 2
- A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid TumorsRecruitingNCT07115043Phase 1/2
- Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid TumorsRecruitingNCT07006727Phase 1
- Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell CarcinomaRecruitingNCT06947928Phase 2/3
- IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)RecruitingNCT06940440Phase 1
- Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing TumorsRecruitingNCT06814496Phase 1/2
- Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any HistotypeRecruitingNCT06753136Not applicable
- Personalised Immunotherapy PlatformRecruitingNCT06536257
- Identification and Characterization of Circulating Tumor Cells Before and After Treatment (Surgery and Radiotherapy) in a Cohort of Patients Treated for Resectable Stage I-III Merkel Cell CarcinomaNot yet recruitingNCT06448611
- EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin CancersRecruitingNCT06223659Phase 2
- Neoadjuvant Nivolumab and Relatlimab in Merkel Cell CarcinomaRecruitingNCT06151236Phase 2
- Study of PembrolizumAb combiNeD With Cisplatin or carbOplatin and Etoposide in Treatment naïve Advanced meRkel Cell cArcinoma (MCC)Not yet recruitingNCT06086288Phase 2
- Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain MetastasisRecruitingNCT06047379Phase 1/2
- Exploring Merkel Cell Carcinoma Clinical Trial Engagement PatternsNot yet recruitingNCT06039033
- A Study of CRD3874-SI in People With Solid TumorsRecruitingNCT06021626Phase 1
- Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin CancerRecruitingNCT05896839Phase 1/2
- A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor CancerRecruitingNCT05859074Phase 1
- Sentinel Lymph Node Biopsy in Ocular Surface and Adnexal CancersRecruitingNCT05797415
- A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid TumorsRecruitingNCT05592626Phase 1/2
- Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell CancerRecruitingNCT05583708Phase 2
- Neoadjuvant PD-1 Blockade in Resectable Merkel Cell CarcinomaRecruitingNCT05496036Phase 2
- L19IL2/L19TNF in Skin Cancer PatientsRecruitingNCT05329792Phase 2
- Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid TumorsRecruitingNCT05269381Phase 1/2
- Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic CancerRecruitingNCT05267626Phase 1/2
- Hypofractionated Radiation Therapy for Merkel Cell CarcinomaRecruitingNCT05100095Phase 2
- A Beta-only IL-2 ImmunoTherapY StudyRecruitingNCT05086692Phase 1/2
- MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid TumorsRecruitingNCT05076760Phase 1
- Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell CarcinomaRecruitingNCT04975152Phase 1
- IFx-Hu2.0 Expanded Access ProgramAvailableNCT04853602
- Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell CarcinomaRecruitingNCT03787602Phase 1/2
- French National Database of Rare Dermatological CancersRecruitingNCT03210935
- Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC VirusRecruitingNCT02479698Phase 2
- Studies of Dermatologic Diseases Biospecimen Acquisition ProtocolRecruitingNCT02471352
- A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic CancerTerminatedNCT04916002Phase 2Results posted
- Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell CarcinomaActive, not recruitingNCT04869137Phase 2Results posted
- Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung CancerTerminatedNCT04590781Phase 1/2Results posted
- Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid TumorsTerminatedNCT04234113Phase 1Results posted
- Palliative RT & Anti-PD-1/PD-L1 Checkpoint Blockade in Metastatic Merkel Cell CarcinomaTerminatedNCT03988647Phase 2Results posted
- High-Risk Skin Cancers With Atezolizumab Plus NT-I7TerminatedNCT03901573Phase 1/2Results posted
- QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint TherapyTerminatedNCT03853317Phase 2Results posted
- Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic CancersActive, not recruitingNCT03816332Phase 1Results posted
- Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913)CompletedNCT03783078Phase 3Results posted
- A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)CompletedNCT03599713Phase 2Results posted
- REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor MalignanciesTerminatedNCT03435640Phase 1/2Results posted
- Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell CarcinomaCompletedNCT03304639Phase 2Results posted
- Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic MalignanciesCompletedNCT03126110Phase 1/2Results posted
- Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell CarcinomaActive, not recruitingNCT03071406Phase 2Results posted
- A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid TumorsCompletedNCT02819843Phase 2Results posted
- A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible CancersCompletedNCT02643303Phase 1/2Results posted
- Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell CarcinomaTerminatedNCT02584829Phase 1/2Results posted
- MLN0128 in Recurrent/Metastatic Merkel Cell CarcinomaCompletedNCT02514824Phase 1/2Results posted
- QUILT-3.009: Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC)TerminatedNCT02465957Phase 2Results posted
- Pembrolizumab in Treating Patients With Advanced Merkel Cell CancerCompletedNCT02267603Phase 2Results posted
- Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200)CompletedNCT02155647Phase 2Results posted
- Cabozantinib in Recurrent/Metastatic Merkel Cell CarcinomaTerminatedNCT02036476Phase 2Results posted
- IL-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Patients With Merkel Cell CancerCompletedNCT01440816Phase 2Results posted
- The Impact of Total Body Skin Examination on Skin Cancer DetectionCompletedNCT00765193Not applicableResults posted
- Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )TerminatedNCT06939036Phase 1/2
- Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell CarcinomaActive, not recruitingNCT06056895Phase 2
- Exercise to Boost Response to Checkpoint Blockade ImmunotherapyActive, not recruitingNCT06008977Not applicable
- Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX TrialActive, not recruitingNCT05947500Phase 2
- A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid TumorsCompletedNCT05864144Phase 1/2
- Chemo-immunotherapy in Patients With Resectable Merkel Cell Carcinoma Prior to SurgeryActive, not recruitingNCT05594290Phase 2
- Immunological Variables Associated to ICI Toxicity in Cancer PatientsStatus unknownNCT05429866Phase 2
- Study To Evaluate The Safety, Tolerability And Immunogenicity Of 4 mg Of ITI-3000 In Patients With Polyomavirus-Positive Merkel Cell Carcinoma (MCC)CompletedNCT05422781Phase 1
- Exercise to Boost Response to Checkpoint Blockade ImmunotherapyActive, not recruitingNCT05358938Early Phase 1
- Comparing Radical Surgery and Radical Radiotherapy as First Definitive Treatment for Primary MCCCompletedNCT05253144Not applicable
- BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid TumorsActive, not recruitingNCT05120271Phase 1/2
- Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IOActive, not recruitingNCT05078047Phase 3
- Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic MalignanciesActive, not recruitingNCT05013099Phase 2
- Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic Merkel Cell Carcinoma (MERKLIN 1)WithdrawnNCT04874831Phase 2
- Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell CarcinomaActive, not recruitingNCT04792073Phase 2
- A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid TumorsTerminatedNCT04725331Phase 1/2
- SerUM Markers in MERkel Cell Carcinoma Patients: a Longitudinal moniTorIng Study for optiMization of European GuidelinesActive, not recruitingNCT04705389Not applicable
- Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced CancerCompletedNCT04670445Not applicable
- In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid TumorsActive, not recruitingNCT04616248Phase 1
- TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell TherapyTerminatedNCT04596033Phase 1
- Study of PF-07265807 in Participants With Metastatic Solid Tumors.TerminatedNCT04458259Phase 1
- Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1CompletedNCT04393753Phase 2
- Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin MalignanciesActive, not recruitingNCT04349436Phase 1/2
- Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell CarcinomaActive, not recruitingNCT04291885Phase 2
- Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.WithdrawnNCT04276597Phase 2
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid TumorsTerminatedNCT04272034Phase 1
- Targeted Therapy and Avelumab in Merkel Cell CarcinomaActive, not recruitingNCT04261855Phase 1/2
- A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic CancersTerminatedNCT04260802Phase 1/2
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid TumorsCompletedNCT04242199Phase 1
- LITT and Pembrolizumab in Recurrent Brain MetastasisTerminatedNCT04187872Phase 1
- Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin CancersCompletedNCT04160065Phase 1
- Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid TumorsCompletedNCT04157985Phase 3
- Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid TumorsTerminatedNCT04116320Phase 1
- Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular ImmunotherapyTerminatedNCT04106167
- A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Merkel Cell CarcinomaActive, not recruitingNCT04047251Phase 1
- Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid CancersActive, not recruitingNCT03935893Phase 2
- FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid TumorsCompletedNCT03841110Phase 1